Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Vet Ther ; 6(2): 96-112, 2005.
Article in English | MEDLINE | ID: mdl-16094558

ABSTRACT

The efficacy of tulathromycin in the treatment of bovine respiratory disease (BRD) due to Mycoplasma bovis was determined following experimental infection. Two highly pathogenic strains of M. bovis (with minimum inhibitory concentration values for tulathromycin of 1 and >64 microg/ml) were inoculated into 145 calves. Four days after inoculation, calves with clinical BRD were treated subcutaneously with saline or tulathromycin (2.5 mg/kg). Compared with saline, BRD-related withdrawals, peak rectal temperatures, and lung lesion scores were significantly lower for tulathromycin-treated calves (P < .01). Tulathromycin was highly effective in the treatment of BRD due to M. bovis in calves regardless of the minimum inhibitory concentration of the challenge strain (1 or >64 microg/ml).


Subject(s)
Anti-Bacterial Agents/therapeutic use , Cattle Diseases/drug therapy , Disaccharides/therapeutic use , Heterocyclic Compounds/therapeutic use , Mycoplasma Infections/veterinary , Mycoplasma bovis , Animals , Animals, Newborn , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Body Temperature , Cattle , Cattle Diseases/microbiology , Cattle Diseases/pathology , Dairying , Disaccharides/administration & dosage , Disaccharides/pharmacology , Female , Heterocyclic Compounds/administration & dosage , Heterocyclic Compounds/pharmacology , Injections, Subcutaneous/veterinary , Male , Microbial Sensitivity Tests , Mycoplasma Infections/drug therapy , Mycoplasma bovis/classification , Mycoplasma bovis/drug effects , Severity of Illness Index , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...